How has the Cytiva acquisition impacted Danaher's financial performance?

The acquisition of Cytiva, completed on March 31, 2020, significantly boosted Danaher's top-line performance. In the third quarter of 2020, Cytiva contributed 24.5% to the company's overall revenue growth of 34.5%. The Life Sciences segment, which now includes Cytiva, saw its revenue increase by 72.5% year-over-year, with core sales including Cytiva growing by 18.5%. While Cytiva's integration resulted in significant acquisition-related charges impacting operating profit margins in the short term, management views it as a key driver of future sales and earnings growth.

What is the impact of COVID-19 on Danaher's business?

The COVID-19 pandemic has had a mixed impact. It has driven significant demand for certain products and services, particularly in the Life Sciences (e.g., bioprocessing for vaccines) and Diagnostics (e.g., COVID-19 testing) segments, contributing positively to revenue growth. However, the pandemic has also created disruptions, negatively affecting demand for non-COVID related research and elective procedures in some areas. Danaher is actively managing these impacts through business continuity plans and expects COVID-19 related demand to continue into Q4 2020, but anticipates this will subside as the pandemic wanes. The company acknowledges the ongoing uncertainty and potential for material negative impacts.

How has Danaher managed its debt and capital structure following the Cytiva acquisition?

The Cytiva acquisition significantly increased Danaher's outstanding debt to approximately $21.8 billion as of October 2, 2020. To manage this, the company took several financing actions, including borrowing under credit facilities and issuing Euro-denominated debt in March and April 2020. They also raised capital through common and preferred stock offerings in May 2020. Danaher is actively managing its debt service obligations and has stated that its operating cash flows, cash on hand, and other liquidity sources are sufficient to meet its obligations. The company is also planning to redeem certain notes in Q4 2020.

What were the key drivers for the increase in operating cash flow?

Operating cash flow from continuing operations saw a substantial increase of approximately 50% year-over-year for the nine-month period ended October 2, 2020. This growth was primarily driven by higher net earnings (after adjusting for non-cash items), improved cash collections from trade receivables, and favorable movements in prepaid expenses and other assets, as well as accrued expenses and liabilities. These positive factors more than offset increased cash usage for inventories and trade payables.

DHR 10-Q Filed Oct 22, 2020

Summary

Danaher Corporation's (DHR) third quarter 2020 results demonstrated resilience and growth, driven significantly by the recent acquisition of Cytiva and increased demand for COVID-19 related products. Overall revenues surged by 34.5%, with Cytiva contributing 24.5% to this growth. Core sales, excluding acquisitions and currency impacts, rose by 9.0%, indicating strong underlying performance across existing businesses. The company saw improved sequential performance from Q2 to Q3, particularly in Life Sciences and Diagnostics segments, which benefited from increased demand in bioprocessing, filtration, genomic solutions, and molecular/acute care testing. While the COVID-19 pandemic continues to pose risks and has impacted some segments negatively, the company's diversified business model and strategic focus on high-growth markets and products have enabled it to navigate the challenging environment effectively. Financially, Danaher reported net earnings from continuing operations of $884 million for the quarter, a significant increase from the prior year, with diluted EPS at $1.16. The company generated substantial operating cash flow, up 50% year-over-year, despite significant investments in acquisitions. The balance sheet remains robust, with approximately $5.7 billion in cash and cash equivalents as of October 2, 2020. Management expressed confidence in its ability to fund ongoing operations, investments, and debt obligations, supported by its diversified business and strong cash generation.

Key Highlights

1Total revenues increased by 34.5% year-over-year in Q3 2020, largely driven by the Cytiva acquisition ($20.7 billion, closed March 31, 2020) which contributed 24.5% to revenue growth.
2Core sales (excluding acquisitions and currency) grew 9.0% in Q3 2020, indicating healthy organic growth in existing businesses.
3Life Sciences segment revenue surged 72.5% due to Cytiva, with its core sales (including Cytiva) growing 18.5%. This segment benefited from demand for bioprocessing, filtration, and genomic solutions related to COVID-19 research and vaccine development.
4Diagnostics segment saw strong demand for molecular and acute care testing solutions, driving 18.0% revenue growth and 17.5% core sales growth in Q3 2020.
5Net earnings from continuing operations were $884 million ($1.16 per diluted share) for Q3 2020, up significantly from $631 million ($0.89 per diluted share) in Q3 2019.
6Operating cash flow from continuing operations increased by approximately 50% year-over-year for the nine-month period ended October 2, 2020, reaching $3.99 billion.
7The company generated a pretax gain of $455 million ($305 million after-tax) from the divestiture of certain Life Sciences product lines related to regulatory approval for the Cytiva acquisition.

DANAHER CORP /DE/ Quarterly Report for Q3 Ended Oct 2, 2020

Summary

Key Highlights

Frequently Asked Questions